Lab
Charles River Medical Associates, PC
Charles River Medical Associates, PC was paid $1.41M by Medicaid between Jan 2018 and Dec 2024, across 70 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 13% of everything it billed.
33Billing provider infoCHARLES RIVER MEDICAL ASSOCIATES, PC
FRAMINGHAM, MA 01702
FRAMINGHAM, MA 01702
33aNPI1801857537assigned 03/31/2006
33bProvider typeClinical Medical Laboratory
28Total paid$1.41M
24GClaims237,072
24DCodes billed70
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Massachusetts
Rank by total paid#21 of 63
Median peer was paid$473K
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,079 | $237K | |
| 2019 | 35,252 | $191K | |
| 2020 | 30,507 | $169K | |
| 2021 | 39,021 | $289K | |
| 2022 | 36,858 | $250K | |
| 2023 | 32,942 | $164K | |
| 2024incomplete | 26,413 | $112K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13% | 2,915 | 2,575 | $186K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 12% | 14,075 | 13,916 | $175K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12% | 5,918 | 5,140 | $173K |
| 84443 | Thyroid stimulating hormone (TSH) | 9.2% | 17,659 | 17,289 | $130K |
| 80053 | Comprehensive metabolic panel | 6.5% | 27,357 | 26,049 | $92K |
| 80061 | Lipid panel | 6.1% | 19,660 | 19,468 | $86K |
| 85027 | 4.8% | 24,980 | 23,793 | $68K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 4.3% | 17,943 | 17,697 | $61K |
| 82607 | 3.8% | 10,052 | 9,765 | $54K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.3% | 2,445 | 2,170 | $47K |
| 83970 | 2.5% | 3,007 | 2,966 | $35K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.8% | 1,163 | 1,074 | $26K |
58 more codes
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.6% | 1,023 | $22K |
| 82728 | 1.5% | 4,552 | $21K | |
| 84439 | 1.4% | 5,130 | $20K | |
| 82746 | 1.2% | 3,056 | $16K | |
| 83550 | 1.2% | 5,436 | $16K | |
| ATP17 | 1.1% | 5,764 | $15K | |
| 84153 | <1% | 1,603 | $14K | |
| 82043 | <1% | 6,903 | $12K | |
| 83540 | <1% | 5,444 | $12K | |
| 82570 | <1% | 6,864 | $12K | |
| 86803 | <1% | 1,100 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,712 | $9K |
| ATP14 | <1% | 3,996 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,623 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 118 | $6K |
| 86140 | <1% | 2,501 | $6K | |
| 83735 | <1% | 3,015 | $6K | |
| 81003 | <1% | 4,694 | $5K | |
| 85651 | <1% | 2,584 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,244 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 133 | $3K |
| 84480 | <1% | 488 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 126 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 126 | $3K |
| 86769 | <1% | 116 | $3K | |
| ATP15 | <1% | 1,386 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 142 | $3K |
| 83615 | <1% | 2,602 | $3K | |
| 86703 | <1% | 303 | $3K | |
| 80076 | <1% | 952 | $3K | |
| ATP18 | <1% | 769 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 207 | $2K |
| 87088 | <1% | 701 | $2K | |
| 81001 | <1% | 1,669 | $2K | |
| 87186 | <1% | 595 | $2K | |
| 83721 | <1% | 1,945 | $2K | |
| 82378 | <1% | 248 | $2K | |
| 84550 | <1% | 1,232 | $1K | |
| ATP08 | <1% | 689 | $1K | |
| 82248 | <1% | 855 | $1K | |
| 84100 | <1% | 879 | $625.05 | |
| 80069 | <1% | 310 | $463.57 | |
| 81015 | <1% | 1,250 | $306.69 | |
| 82550 | <1% | 111 | $258.30 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 33 | $256.55 |
| 87480 | <1% | 14 | $248.99 | |
| 87510 | <1% | 14 | $248.99 | |
| 87660 | <1% | 14 | $248.99 | |
| 82150 | <1% | 56 | $128.57 | |
| 85045 | <1% | 98 | $118.39 | |
| 86780 | <1% | 12 | $87.38 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 320 | $71.00 |
| ATP13 | <1% | 13 | $55.20 | |
| ATP10 | <1% | 13 | $45.45 | |
| 84460 | <1% | 12 | $18.03 | |
| 84436 | <1% | 12 | $16.54 | |
| 82040 | <1% | 15 | $10.57 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 0% | 76 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPARILLO, BRIAN (EXECUTIVE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Charles River Medical Associates PC | Framingham, MA | $567K |
| Charles River Medical Associates, PC | Framingham, MA | $61K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.